Protagonist Therapeutics (PTGX) Liabilities and Shareholders Equity (2015 - 2026)

Protagonist Therapeutics has disclosed Liabilities and Shareholders Equity across 12 years of filings, most recently posting $697.5 million for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $697.5 million, down 6.02% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.8 billion (up 2.96% YoY), and the FY2025 annual result was $668.2 million, down 10.28% from the prior year.
• Liabilities and Shareholders Equity came in at $697.5 million for Q1 2026 at Protagonist Therapeutics, up from $668.2 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $744.7 million in Q4 2024 to a low of $239.9 million in Q1 2023.
• The 5-year median for Liabilities and Shareholders Equity is $603.9 million (2024), against an average of $503.4 million.
• Across the five-year window, Liabilities and Shareholders Equity tumbled 31.13% in 2023 and surged 162.35% in 2024, its largest moves.
• Protagonist Therapeutics' Liabilities and Shareholders Equity stood at $247.9 million in 2022, then jumped by 44.38% to $358.0 million in 2023, then surged by 108.05% to $744.7 million in 2024, then dropped by 10.28% to $668.2 million in 2025, then advanced by 4.38% to $697.5 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $697.5 million (Q1 2026), $668.2 million (Q4 2025), and $701.7 million (Q3 2025), per Business Quant data.